TERT promoter mutations in melanoma render TERT expression dependent on MAPK pathway activation

Oncotarget

Volumn 7, Issue 33, 2016, Pages 53127-53136

  Vallarelli, Andrelou F ^a,b,c   Rachakonda, P Sivaramakrishna ^d   André, Jocelyne ^a,b   Heidenreich, Barbara ^d   Riffaud, Laurence ^a,b   Bensussan, Armand ^a,b   Kumar, Rajiv ^d   Dumaz, Nicolas ^a,b  

^a SAINT LOUIS HOSPITAL   (France)

^b UNIVERSITÉ PARIS DESCARTES   (France)

^c UNIVERSITY OF CAMPINAS   (Brazil)

^d GERMAN CANCER RESEARCH CENTER DKFZ   (Germany)

Author keywords

BRAF; ETS1; MAPK pathway; Melanoma; Telomerase

Indexed keywords

B RAF KINASE; MITOGEN ACTIVATED PROTEIN KINASE; NRAS PROTEIN; RAS PROTEIN; TELOMERASE REVERSE TRANSCRIPTASE; THREONINE; TRANSCRIPTION FACTOR ETS 1; UNCLASSIFIED DRUG; BRAF PROTEIN, HUMAN; GUANOSINE TRIPHOSPHATASE; MEMBRANE PROTEIN; NRAS PROTEIN, HUMAN; TELOMERASE;

ARTICLE; BINDING SITE; CONTROLLED STUDY; ENZYME ACTIVATION; GENE EXPRESSION REGULATION; GENE MUTATION; HUMAN; HUMAN CELL; MELANOMA; MELANOMA CELL LINE; PROMOTER REGION; PROTEIN BINDING; PROTEIN EXPRESSION; PROTEIN PHOSPHORYLATION; TERT GENE; TRANSCRIPTION REGULATION; GENETICS; MAPK SIGNALING; METABOLISM; MUTATION; PATHOLOGY; RNA INTERFERENCE; TUMOR CELL LINE;

CELL LINE, TUMOR; GENE EXPRESSION REGULATION, NEOPLASTIC; GTP PHOSPHOHYDROLASES; HUMANS; MAP KINASE SIGNALING SYSTEM; MELANOMA; MEMBRANE PROTEINS; MUTATION; PROMOTER REGIONS, GENETIC; PROTO-ONCOGENE PROTEIN C-ETS-1; PROTO-ONCOGENE PROTEINS B-RAF; RNA INTERFERENCE; TELOMERASE;

EID: 84982304814     PISSN: None     EISSN: 19492553     Source Type: Journal    
DOI: 10.18632/oncotarget.10634     Document Type: Article

References (28)

1. Genomic Classification of Cutaneous Melanoma. Cell. 2015; 161:1681-1696.
2. Pollock PM, Harper UL, Hansen KS, Yudt LM, Stark M, Robbins CM, Moses TY, Hostetter G, Wagner U, Kakareka J, Salem G, Pohida T, Heenan P, et al. High frequency of BRAF mutations in nevi. Nature genetics. 2003; 33:19-20.
3. Michaloglou C, Vredeveld LC, Soengas MS, Denoyelle C, Kuilman T, van der Horst CM, Majoor DM, Shay JW, Mooi WJ, Peeper DS. BRAFE600-associated senescence-like cell cycle arrest of human naevi. Nature. 2005; 436:720-724.
4. Martinez P, Blasco MA. Telomeric and extra-telomeric roles for telomerase and the telomere-binding proteins. Nature reviews Cancer. 2011; 11:161-176.
5. Xu L, Li S, Stohr BA. The role of telomere biology in cancer. Annu Rev Pathol. 2013; 8:49-78.
6. Miracco C, Margherita De Santi M, Schurfeld K, Santopietro R, Lalinga AV, Fimiani M, Biagioli M, Brogi M, De Felice C, Luzi P, Andreassi L. Quantitative in situ evaluation of telomeres in fluorescence in situ hybridization-processed sections of cutaneous melanocytic lesions and correlation with telomerase activity. The British journal of dermatology. 2002; 146:399-408.
7. Huang FW, Hodis E, Xu MJ, Kryukov GV, Chin L, Garraway LA. Highly recurrent TERT promoter mutations in human melanoma. Science (New York, NY. 2013; 339:957-959.
8. Horn S, Figl A, Rachakonda PS, Fischer C, Sucker A, Gast A, Kadel S, Moll I, Nagore E, Hemminki K, Schadendorf D, Kumar R. TERT promoter mutations in familial and sporadic melanoma. Science (New York, NY. 2013; 339:959-961.
9. Heidenreich B, Rachakonda PS, Hemminki K, Kumar R. TERT promoter mutations in cancer development. Current opinion in genetics & development. 2014; 24:30-37.
10. Heidenreich B, Nagore E, Rachakonda PS, Garcia-Casado Z, Requena C, Traves V, Becker J, Soufir N, Hemminki K, Kumar R. Telomerase reverse transcriptase promoter mutations in primary cutaneous melanoma. Nat Commun. 2014; 5:3401.
11. Nagore E, Heidenreich B, Rachakonda S, Garcia-Casado Z, Requena C, Soriano V, Frank C, Traves V, Quecedo E, Sanjuan-Gimenez J, Hemminki K, Landi MT, Kumar R. TERT promoter mutations in melanoma survival. International journal of cancer. 2016; 139:75-84.
12. Shain AH, Yeh I, Kovalyshyn I, Sriharan A, Talevich E, Gagnon A, Dummer R, North J, Pincus L, Ruben B, Rickaby W, D'Arrigo C, Robson A, et al. The Genetic Evolution of Melanoma from Precursor Lesions. The New England journal of medicine. 2015; 373:1926-1936.
13. Hollenhorst PC, McIntosh LP, Graves BJ. Genomic and biochemical insights into the specificity of ETS transcription factors. Annual review of biochemistry. 2011; 80:437-471.
14. Wei GH, Badis G, Berger MF, Kivioja T, Palin K, Enge M, Bonke M, Jolma A, Varjosalo M, Gehrke AR, Yan J, Talukder S, Turunen M, et al. Genome-wide analysis of ETS-family DNA-binding in vitro and in vivo. The EMBO journal. 2010; 29:2147-2160.
15. Charlot C, Dubois-Pot H, Serchov T, Tourrette Y, Wasylyk B. A review of post-translational modifications and subcellular localization of Ets transcription factors: possible connection with cancer and involvement in the hypoxic response. Methods Mol Biol. 2010; 647:3-30.
16. Bell RJ, Rube HT, Kreig A, Mancini A, Fouse SD, Nagarajan RP, Choi S, Hong C, He D, Pekmezci M, Wiencke JK, Wrensch MR, Chang SM, et al. Cancer. The transcription factor GABP selectively binds and activates the mutant TERT promoter in cancer. Science (New York, NY. 2015; 348:1036-1039.
17. Li Y, Zhou QL, Sun W, Chandrasekharan P, Cheng HS, Ying Z, Lakshmanan M, Raju A, Tenen DG, Cheng SY, Chuang KH, Li J, Prabhakar S, et al. Non-canonical NFkappaB signalling and ETS1/2 cooperatively drive C250T mutant TERT promoter activation. Nature cell biology. 2015; 17:1327-1338.
18. Makowski MM, Willems E, Fang J, Choi J, Zhang T, Jansen PW, Brown KM, Vermeulen M. An interaction proteomics survey of transcription factor binding at recurrent TERT promoter mutations. Proteomics. 2015.
19. Odrowaz Z, Sharrocks AD. The ETS transcription factors ELK1 and GABPA regulate different gene networks to control MCF10A breast epithelial cell migration. PLoS One. 2012; 7:e49892.
20. Chiba K, Johnson JZ, Vogan JM, Wagner T, Boyle JM, Hockemeyer D. Cancer-associated TERT promoter mutations abrogate telomerase silencing. Elife. 2015; 4.
21. Stern JL, Theodorescu D, Vogelstein B, Papadopoulos N, Cech TR. Mutation of the TERT promoter, switch to active chromatin, and monoallelic TERT expression in multiple cancers. Genes & development. 2015; 29:2219-2224.
22. Dittmer J. The biology of the Ets1 proto-oncogene. Molecular cancer. 2003; 2:29.
23. Seth A, Watson DK. ETS transcription factors and their emerging roles in human cancer. Eur J Cancer. 2005; 41:2462-2478.
24. Rothhammer T, Hahne JC, Florin A, Poser I, Soncin F, Wernert N, Bosserhoff AK. The Ets-1 transcription factor is involved in the development and invasion of malignant melanoma. Cell Mol Life Sci. 2004; 61:118-128.
25. Torlakovic EE, Bilalovic N, Nesland JM, Torlakovic G, Florenes VA. Ets-1 transcription factor is widely expressed in benign and malignant melanocytes and its expression has no significant association with prognosis. Mod Pathol. 2004; 17:1400-1406.
26. Foulds CE, Nelson ML, Blaszczak AG, Graves BJ. Ras/ mitogen-activated protein kinase signaling activates Ets-1 and Ets-2 by CBP/p300 recruitment. Molecular and cellular biology. 2004; 24:10954-10964.
27. Selvaraj N, Kedage V, Hollenhorst PC. Comparison of MAPK specificity across the ETS transcription factor family identifies a high-affinity ERK interaction required for ERG function in prostate cells. Cell communication and signaling. 2015; 13:12.
28. Rachakonda PS, Hosen I, de Verdier PJ, Fallah M, Heidenreich B, Ryk C, Wiklund NP, Steineck G, Schadendorf D, Hemminki K, Kumar R. TERT promoter mutations in bladder cancer affect patient survival and disease recurrence through modification by a common polymorphism. Proceedings of the National Academy of Sciences of the United States of America. 2013; 110:17426-17431.